Ascentage Pharma Group International (NASDAQ:AAPG) Releases Earnings Results

Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.65) EPS for the quarter, reports. The firm had revenue of $22.24 million during the quarter.

Ascentage Pharma Group International Stock Performance

Shares of AAPG stock opened at $17.32 on Friday. Ascentage Pharma Group International has a 12 month low of $16.36 and a 12 month high of $48.45. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79. The company’s fifty day moving average price is $18.21 and its 200-day moving average price is $21.23.

Get Ascentage Pharma Group International alerts:

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in AAPG. UBS Group AG raised its position in shares of Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares during the last quarter. Hsbc Holdings PLC purchased a new stake in Ascentage Pharma Group International during the 2nd quarter valued at about $391,000. Finally, Citadel Advisors LLC purchased a new stake in Ascentage Pharma Group International during the 3rd quarter valued at about $383,000.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Ascentage Pharma Group International in a research report on Friday, April 24th. They set a “buy” rating and a $40.00 price target on the stock. BTIG Research restated a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Friday. Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. Finally, B. Riley Financial began coverage on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. They set a “buy” rating and a $45.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $46.43.

Read Our Latest Report on Ascentage Pharma Group International

Ascentage Pharma Group International Company Profile

(Get Free Report)

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.

Read More

• Five stocks we like better than Ascentage Pharma Group International
• SK hynix Triggers $28B Defense Against Tech Selloff
• Coherent Stock Is Cooling Off Just as Its AI Thermal Opportunity Heats Up
• Moderna’s 177% Surge Has Investors Asking What Comes Next
• 3 Energy Stocks Raising Dividends as the Sector Surges

Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.